Anela Blazevic

Anela Blazevic is a Researcher in the Department of Internal Medicine at Erasmus MC, Erasmus University Rotterdam, specializing in neuroendocrine tumor pathophysiology with emphasis on mesenteric fibrosis, sex-based differences, and radionuclide therapies. Her work bridges molecular oncology and clinical endocrinology to address critical gaps in neuroendocrine tumor management.

Her educational background includes:

• PhD in Medicine, Erasmus University Rotterdam, 2023 (Thesis: Mesenteric fibrosis in neuroendocrine tumors: An entangled conundrum)

Dr. Blazevic's research explores proteomic signatures of small intestinal neuroendocrine tumors (SI-NETs), hormonal influences on disease progression, and metabolic dysregulation in tumor stroma. She pioneered investigations into sexual dimorphism revealing reduced mesenteric disease prevalence in premenopausal women and characterized tryptophan metabolism abnormalities driving fibrosis. Her clinical work evaluates Lu-DOTATATE therapy efficacy for carcinoid syndrome, with findings directly impacting treatment protocols.

Analysis of her 2021-2023 publications reveals three dominant trajectories: (1) proteomic profiling of SI-NETs identifying fibrosis biomarkers, (2) epidemiological studies of sex differences highlighting hormonal protection mechanisms, and (3) clinical optimization of peptide receptor radionuclide therapy. Her 2021 therapy study achieved significant impact with 39 Scopus citations and clinical guideline inclusion, while her 2022 sex-differences paper demonstrates translational relevance through 18 citations.